References

bekhterev

Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева

V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

2313-70532713-055X

V. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH

bekhterev-16

Research Article

В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ

GUIDELINES FOR THE PRACTITIONER

Церебролизин: спектр активности и данные исследований (часть 2)

Cerebrolysin: spectrum of activity and research data. Part 2

Букреева

Наталья Дмитриевна

Bukreeva

N. D.

ndbukreeva@yandex.ru

Ракитянская

Елизавета Александровна

Rakityanskaya

E. A.

earakityanskaya@yandex.ru

ФГБУ «ФМИЦПН им. В.П. Сербского» Минздрава РоссииRussian Federation

2016

19072018

024152

2018

Букреева Н.Д., Ракитянская Е.А.

Bukreeva N.D., Rakityanskaya E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.bekhterevreview.com/jour/article/view/16

Как показывают результаты анализа экспериментальных и клинических исследований, применение церебролизина является эффективной и безопасной терапией при многих неврологических расстройствах, начиная от инсульта и заканчивая болезнью Альцгеймера. Первичный эффект препарата связан с влиянием церебролизина на определенные зоны гиппокампа и их функцию. Препарат обладает уникальным органоспецифическим мультимодальным действием на головной мозг, способен к метаболической регуляции, нейропротекции, функциональной нейромодуляции и нейротро-фической активности, установленным в многочисленных экспериментальных исследованиях. Клиническая эффективность препарата подтверждена в ходе клинических испытаний, проводившихся с учетом требований GCP.

The results of analysis of experimental and clinical studies have shown that Cerebrolysin application is safe and effective therapy for many neurological disorders ranging from stroke and ending Alzheimer’s disease. The primary effect of the medicine is associated with the influence of Cerebrolysin on certain areas of the hippocampus and their function. The medicine has a unique organ-multimodal action on the brain, it is capable of metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity, detected in numerous experimental studies. The clinical efficacy of the medicine is confirmed by clinical trials performed based on GCP requirements.

ЦеребролизинЛекарственная терапияПсихиатрияНеврологияФармакологияНейропротекторМетаболическая регуляцияФункциональная нейромодуляцияCerebrolysinMedical therapyPsychiatryNeurologyPharmacologyNeuroprotectiveMetabolic regulationFunctional NeuromodulationNeurotrophic Activity

References1

Akai F., Hiruma S., Sato T., Iwamoto N., Fujimoto M., Ioku M. and Hashimoto S. Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. - Histol Histopathol. - 1992. - Vol. 7. - P. 213-21.

Alvarez X.A., Cacabelos R., Laredo M., Couceiro V., Sampedro C., Varela M., Corzo L., Fernandez-Novoa L., Vargas M., Aleixandre M., Linares C., Granizo E., Muresanu D. and Moessler H. A 24-week, doubleblind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. - Eur J Neurol. - 2006. - Vol. 3. - P. 43-54.

Alvarez X.A., Lombardi V.R., Fernandez-Novoa L., Garcia M., Sampedro C., Cagiao A., Cacabe-los R. and Windisch M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. - J Neural Transm Suppl. - 2000. - Vol.59. - P. 281-292.

Alvarez X.A., Sampedro C., Perez P., Laredo M., Couceiro V., Hernandez A., Figueroa J., Varela M., Arias D., Corzo L., Zas R., Lombardi V., Fernandez-Novoa L., Pichel V., Cacabelos R., Windisch M., Aleixandre M. and Moessler H. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. - Int Clin Psychopharma-col. - 2003. - Vol. 18. - P. 271-278.

Bae C.Y., Cho C.Y., Cho K., Hoon Oh. B., Choi K.G., Lee H.S., Jung S.P., Kim D.H., Lee S., Choi G.D., Cho H. and Lee H. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. - J Am Geriatr Soc. - 2000. - Vol. 48. - P. 1566-1571.

Bayer E. [Therapy with the cerebral hydrolysate cerebrolysin. A practice report]. - Med Welt. -1980. - Vol. 31. - P. 636-637.

Bespalova M.A., Kliaich K., Maksimova S.P., Chae-va L.S. and Mukhina A.P. [The characteristics of the brain cerebrosides, sulfocerebrosides and gangli-osides in experimental demyelination and cerebrolysin administration]. - Nerv Sist. - 1991. - Vol. 30. - P. 64-71.

Biesenbach G., Grafinger P., Eichbauer-Sturm G. and Zazgornik J. [Cerebrolysin in treatment of painful diabetic neuropathy]. - Wien Med Wochen-schr. - 1997. - Vol. 147. - P. 63-66.

Deigner H.P., Haberkorn U. and Kinscherf R. Apoptosis modulators in the therapy of neuro-degenerative diseases. - Expert Opin Investig Drugs. - 2000. - Vol. 9. - P. 747-764.

Domzal T. and Zaleska B. [Cerebrolysin in treatment of acute ischemic stroke]. - Neurol Neurochir Pol. - 1995. - Vol. 29. - P. 325-331.

Funke M., Fiehler J., Mewes I., Eiselt M., Rother I. and Windisch M. Dose-dependent effects of Cerebrolysin on EEG and shortterm memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. - J Neural Transm Suppl. - 1998. - Vol. 53. - P. 385-398.

Gafurov B.G. and Alikulova N.A. [Clinical and pathogenetical peculiarities and treatment policy in ischemic stroke of elderly and old age]. - Zh Nevrol Psikhiatr Im S S Korsakova. - 2004. - P. 44-46.

Gavrilova S.I., Kolykhalov I.V., Korovaitseva G.I., Zharikov G.A., Kalyn Ia. B. and Selezneva N.D. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer’s disease]. Zh Nevrol Psikhiatr Im S. S. Korsakova. - 2005. - Vol. 105.105. - P. 27-34.

Gorbachevskaya N., Bashina V., Gratchev V. and Iznak A. Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. - Brain Dev. 23 Suppl - 2001. - Vol. 1. - P. 90-93.

Grechko A.T. [The neurotropic activity of peptide immunomodulators]. Eksp Klin Farmakol.- 1998. - Vol. 61. - P. 14-16.

Grundman M., Corey-Bloom J. and Thal L.J. Perspectives in clinical Alzheimer’s disease research and the development of Cerebrolysin Review - Wise Young - Page 19 antidementia drugs. - J Neural Transm Suppl. - 1998. - Vol. 53. - P. 255-275.

Gusev E.I., Burd G.S., Gekht A.B., Skvortsova V.I, Bogomolova M.A., Selikhova M.V. and Fidler S.M. [The clinico-neurophysiological study of the effect of cerebrolysin on brain function in the acute and early recovery periods of hemispheric ischemic stroke]. Zh Nevropatol Psikhiatr Im S.S. Korsakova. - 1994. - Vol. 94. - P. 9-13.

Haninec P., Dubovy P., Samal F., Houstava L. and Stejskal L. Reinnervation of the rat musculocutaneous nerve stump after its direct reconnection with the C5 spinal cord segment by the nerve graft following avulsion of the ventral spinal roots: a comparison of intrathecal administration of brain-derived neurotrophic factor and Cerebrolysin. - Exp Brain Res. - 2004. - Vol. 159. - P. 425-432.

Guekht A.B., Pavlov N. And., Gudkov A.A., Belousov D.Yu., Afanasiev E.V., Belousov Y.B., REP′ev, A.P. Clinical and economic analysis of vascular dementia treatment with Cerebrolysin. // Good clinical practice. - 2001. - Vol. 1. - P. 58-65.

Iakhno N.N., Damulin I.V., Zakharov V.V., Levin O.S. and Elkin M.N. [Experience with using high doses of cerebrolysin in vascular dementia]. - Ter Arkh. - 1996. - Vol. 68. - P. 65-69.

Ishchenko M.M. and Ostrovskaia O.S. [The effect of combined drug treatment on rheologic properties of the blood in patients with disordered circulatory encephalopathy]. - Vrach Delo. - 1990. - P. 58-60.

Kofler B., Erhart C., Erhart P. and Harrer G. [The usefulness of event-related negativity in demonstrating the therapeutic effects of nootropic drugs using cerebrolysin as an example]. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte - Geb. -1990. - Vol. 21. - P. 145-149.

Koppi S. and Barolin G.S. [Use of cerebrolysin in the treatment of ischemic stroke]. Zh Nevrol Psikhiatr Im S.S. Korsakova. - 1998. - Vol. 98. - P. 30-33.

Koroleva V.I., Korolev O.S., Mares V., Pastalkova E. and Bures J. Hippocampal damage induced by carbon monoxide poisoning and spreading depression is alleviated by chronic treatment with brain derived polypeptides. - Brain Res. - 1999. - Vol. 816. - P. 618-627.

Ladurner G., Kalvach P. and Moessler H. Neuro-protective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. - J Neural Transm. -2005. - Vol. 112. - P. 415-428.

Matula C. and Schoeggl A. Cerebral protection before, during and after neurosurgical procedures. - Stereotact Funct Neurosurg. - 2000. - Vol. 75. - P. 142-146.

Molloy D.W. and Standish T.I. Clinical experience with Cerebrolysin. - J Neural Transm Sup-pl. - 2000. - Vol. 59. - P. 293-300.

Muresanu D.F., Rainer M. and Moessler H. Improved global function and activities of daily living in patients with AD: a placebocontrolled clinical study with the neurotrophic agent Cerebrolysin. - J Neural Transm Suppl. - 2002. - P. 277-285.

Nikolov R. Alzheimer’s disease therapy - an update. - Drug News Perspect. - 1998. - Vol. 11. - P. 248-255.

Panisset M., Gauthier S., Moessler H. and Win-disch M. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. - J Neural Transm. - 2002. - Vol. 109. - P. 1089-1104.

Pruszewicz A., Obrebowski A., Woznica B. and Swidzinski P. [Pharmacological possibilities in treatment hypoacusis in children]. - Otolaryngol Pol. - 1994. - Vol. 48. - P. 63-66.

Rainer M., Brunnbauer M., Dunky A., Ender F., Goldsteiner H., Holl O., Kotlan P., Paulitsch G., Reiner C., Stossl J., Zachhuber C. and Mossler H. Therapeutic results with Cerebrolysin in the treatment of dementia. - Wien Med Wochen-schr. - 1997. - Vol. 147. - P. 426-431.

Roshchina I.F., Gavrilova S.I., Zharikov G.A., Kalyn Ia. B., Kolykhalov I.V. and Selezneva N.D. [Neuropsychological evaluation of longterm therapy of Alzheimer’s disease using different cerebrolysin dosages]. - Zh Nevrol Psikhiatr Im S.S. Korsakova. - 2005. - Vol. 105. - P. 52-55.

Roshchina I.F., Kolykhalov I.V., Selezneva N.D., Zharikov G.A., Gerasimov N.P. and Gavrilova S.I. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer’s disease patients [neuropsychological investigation]]. - Zh Nevrol Psikhiatr Im S.S. Korsakova. - 1999. - Vol. 99. - P. 43-46.

Ruether E., Husmann R., Kinzler E., Diabl E., Klingler D., Spatt J., Ritter R., Schmidt R., Taneri Z., Winterer W., Koper D., Kasper S., Rainer M. and Moessler H. A 28-week, double-blind, placebocontrolled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol. - 2001. - Vol. 16. - P. 253-263.

Ruther E., Ritter R., Apecechea M., Freytag S. and Windisch M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type [SDAT]. - Pharmacopsychiatry. - 1994. - Vol. 27. - P. 32-40.

Ruther E., Ritter R., Apecechea M., Freytag S., Gmeinbauer R. and Windisch M. Sustained improvements in patients with dementia of Alzheimer’s type [DAT] 6 months after termination of Cerebrolysin therapy. - J Neural Transm. - 2000 - Vol. 107. - P. 815-829

Shprach V.V., Suvorova I.A. Efficacy of prolonged therapy of vascular dementia // Clinical medicine. - 2011. - Vol. 89, № 5. - P. 57-60.

Sidorenko E.I., Guseva M.R., Dubovskaia L.A. and Lobanova I.V. [Cerebrolysin in the treatment of partial optic atrophy in children]. - Zh Nevropatol Psikhiatr Im S.S. Korsakova. - 1995. - Vol. 95. - P. 51-54.

Skvortsova V.I., Stakhovskaia L.V., Gubskii L.V., Shamalov N.A., Tikhonova I.V. and Smychkov A.S. [A randomized, doubleblind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke]. Zh Nevrol Psikhiatr Im S.S. Korsakova. - 2004. - P. 51-55.

Sotnikova N.Y., Gromova O.A. and Novicova E.A. Dual effect of cerebrolysin in children with attention deficit syndrome with hyperactivity: neuroprotection and immunomodulation. - Russ J Immunol. - 2002. - Vol. 7. - P. 357-364.

Vereshchagin N.V., Nekrasova E.M., Lebedeva N.V., Suslina Z.A., Solov’ev O.I., Piradov M.A. and Altunina M.N. [Mild forms of multiinfarct dementia: effectiveness of cerebrolysin]. - Sov Med. -1991. - P. 6-8.

Vereshchagin N.V., Suslina Z.A., Timerbaeva S.L., Kashina E.M., Gnezditskii V.V., Maksimova M., Rebrova O. and Smirnova I.N. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin]. - Ter Arkh. - 2001. - Vol. 73. - P. 22-27.

Windisch M. Approach towards an integrative drug treatment of Alzheimer’s disease. - J Neural Transm Suppl. - 2005. - Vol. 59. - P. 301-313.

Wong G.K., Zhu X.L. and Poon W.S. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. - Acta Neurochir Suppl. - 2005. - Vol. 95. - P. 59-60.

Ogorodova I.I., T.A. Dubrovskaya, V.I. Zagorodnev. - Correction of speech disorders in children on an outpatient basis. - Consilium Medicum No-2014. - P. 9.

Zavadenko N.N., Suvorinova N.Yu., Rumyantsev M.V., Hyperactivity with attention deficit: risk factors, age dynamics, peculiarities of diagnostics // Defectology. - 2003 - № 6.

Petrukhin A.S. and O.A. Pylaeva in the scientific article «Prospects of using the drug Cerebrolysin in neurology and in clinical practice of the pediatric neurologist» [Russian journal of child neurology. - 2012. - Vol. VII. - P. 3.

Sotnikova N.Yu., Gromova O.A., Novikova E.A. Dual effect of Cerebrolysin in children with attention deficit disorder and hyperactivity: neuroprotection and immunomodulation // Russian journal of immunology. - 2002. - Vol. 4. - P. 357-364.

Batyshev T.T., Bykova O.V., Glazkov V.S., Platonov A.N. Pharmacological treatment of cognitive disorders in children with cerebral palsy - «Cerebrolysin» in pediatric neurological practice // Scientific practical journal «pediatric and adolescent neurology». - 2013. - Vol. 1. - P. 61-70.

Delyagin V.M. speech Delay in children. - RMJ. - 2013. - Vol. 24. - P. 1174.

Bashina, V.M., Diagnosis of childhood autism in chronobiological aspect // Journal of neurology and psychiatry. - 2010. - Vol. 4. - P. 16-24.

Gauthier S., Proano J.V., JiaJ. et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a metaanalysis of randomized controlled clinical trials // Dement Geriatr Cogn Disord. - 2015. - Vol. 39. - P. 332-347.

Muresanu D.F., Heiss W.D., Hoemberg V., Guekht A. et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial // Stroke. - 2016. - Vol. 47. - P. 151-159.

Chen N., Yang M., Guo J. et al. Cerebrolysin for vascular dementia // Cochrane Database Syst Rev. - 2013. - Vol. 1. - P. CD008900.

Hutter-Paier B., Fruhwirth M., Grygar E. and Windisch M. (1996). Cerebrolysin protects neurons from ischemia-induced loss of microtubule-associated protein 2. J Neural Transm Suppl. 47:276.

Chukanova E.I., COMPARATIVE ANALYSIS OF EFFICIENCY CEREBROLYSIN in patients with chronic brain ischemia. Pharmacoeconomic aspects. Article in Journal - scientific article. Tom: 9 Nomer: 1 Year: 2011 Pages: 32-37.

Ruether E., Alvarez X.A., Rainer M. and Moessler H. (2002). Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebocontrolled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 265-75.

Plosker G.L., Adis, a Wolters Kluwer Business, Auckland, New Zealand; Gauthier S., CEREBROLYSIN. A REVIEW OF ITS USE IN DEMENTIA, McGill Center for Studies in Aging, Montreal, Quebec, Canada.

Hecht A.B., Pavlov N. And., Gudkov A.A., Belousov D.Yu., Afanasiev E.V., Belousov Y.B., REP′ev, A.P. Clinical and economic analysis of vascular dementia treatment with Cerebrolysin. // Good clinical practice, № 1, 2011, pp. 58-65.

Panteleyeva G.P., Krylov E.S., Artyukh V.V., Wild T.I., Demeneva A.A. Cere as a means of optimizing the pharmacotherapy of endogenous depression. Psychotherapy, 2008. № 4-6. - S. 70-84.

The authors declare that there are no conflicts of interest present.